BioSpace News Archive

Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure.

The World Health Organization has just featured MediPines AGM100®, pulmonary gas exchange analyzer as an innovative technology in their 2021 compendium, “WHO compendium of innovative health technologies for low-resource settings”.

Glassbeam, Inc., the premier machine data analytics company for the healthcare industry, announced the general availability of the Clinsights Service Analytics app, a revamped product that allows Healthcare organizations to fully monitor, manage, and take remedial service actions in near real-time on radiology equipment.

Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.

Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com ), has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021” (https://www.worldbizmagazine.net/ ).

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, will present efficacy and safety data from its Phase 1b proof of concept study evaluating one application of DMT410 to treat multiple aesthetic skin conditions.

Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon ® platform at the C3i Center Inc (C3i) in Montreal

Horizon Therapeutics plc is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica.

HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

Hemanext Inc. (“Hemanext” or the “Company”), a leading innovator in blood processing and storage technology, today announced that AABB, the leading international not-for-profit association representing healthcare providers and institutions involved in transfusion medicine and biotherapies, has given its Research Innovation in Scientific Excellence (RISE) award.